目次

Table of Contents

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 MARKET STAKEHOLDERS
1.5 LIMITATIONS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 INTRODUCTION
2.1.1 SECONDARY RESEARCH
2.1.2 KEY DATA FROM SECONDARY SOURCES
2.1.2.1 Primary data
2.1.3 KEY DATA FROM PRIMARY SOURCES
2.1.3.1 Insights from primary experts
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION APPROACH
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET OVERVIEW
4.2 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER
4.3 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 REGIONAL MIX: INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2022-2029)

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing prevalence of cardiovascular diseases
5.2.1.2 Rising technological investments in interventional cardiology procedures
5.2.1.3 Increasing prevalence of diabetes
5.2.1.4 Favorable regulatory support
5.2.2 RESTRAINTS
5.2.2.1 Availability of alternative treatments
5.2.2.2 Product recalls
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential in emerging markets
5.2.3.2 Increasing demand for coronary stents
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory requirements for product approvals
5.3 INDUSTRY TRENDS
5.3.1 DRUG-ELUTING TECHNOLOGIES
5.3.2 INCREASING EMPHASIS ON MINIMALLY INVASIVE PROCEDURES
5.4 SUPPLY CHAIN ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 TAVR technology
5.6.2 ADJACENT TECHNOLOGIES
5.6.3 COMPLEMENTARY TECHNOLOGIES
5.6.3.1 Integration of real-time monitoring into wearable technologies
5.6.3.2 Precise cardiovascular interventions through artificial intelligence
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF SUPPLIERS
5.7.4 BARGAINING POWER OF BUYERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY LANDSCAPE
5.8.1 REGULATORY ANALYSIS
5.8.1.1 North America
5.8.1.1.1 US
5.8.1.2 Europe
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
5.9.1 INDICATIVE AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT TYPE, 2023
5.9.2 INDICATIVE AVERAGE SELLING PRICE OF INTERVENTIONAL CARDIOLOGY DEVICES, BY PRODUCT TYPE, 2023
5.9.3 INDICATIVE AVERAGE SELLING PRICE, BY REGION
5.10 ECOSYSTEM ANALYSIS
5.11 PATENT ANALYSIS
5.11.1 PATENT PUBLICATION TRENDS FOR INTERVENTIONAL CARDIOLOGY DEVICES
5.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.12 TRADE ANALYSIS
5.12.1 TRADE ANALYSIS FOR INTERVENTIONAL CARDIOLOGY DEVICES AND CONSUMABLES
5.12.2 HS CODES
5.13 KEY CONFERENCES & EVENTS, 2024−2025
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 UNMET NEEDS/END-USER EXPECTATIONS
5.16 IMPACT OF AI/GEN AI ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET
5.17 CASE STUDY ANALYSIS
5.17.1 CASE STUDY 1: BOSTON SCIENTIFIC CORPORATION USES GUIDEZILLA II EXTENSION CATHETER FOR PC INTERVENTIONS
5.17.2 CASE STUDY 2: MEDTRONIC PROVIDES CARDIOLOGY DEVICES FOR VENOUS INTERVENTIONS
5.17.3 CASE STUDY 3: ABOTT OFFERS DRUG-ELUTING STENTS FOR PATIENTS WITH HIGHER RISK OF STROKE
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.19 ADJACENT MARKETS FOR INTERVENTIONAL CARDIOLOGY DEVICES
5.20 INVESTMENT & FUNDING SCENARIO

6 ANGIOPLASTY STENTS MARKET, BY TYPE
6.1 INTRODUCTION
6.1.1 DRUG-ELUTING STENTS
6.1.1.1 Drug-eluting stents to hold largest share of angioplasty stents market
6.1.2 BARE-METAL STENTS
6.1.2.1 Increasing use of drug-eluting stents to limit growth of bare-metal stents market
6.1.3 BIOABSORBABLE STENTS
6.1.3.1 Ability of bioabsorbable stents to ensure complete healing of arteries to propel demand
?

7 STRUCTURAL HEART DEVICES MARKET, BY TYPE
7.1 INTRODUCTION
7.1.1 AORTIC VALVE THERAPY DEVICES
7.1.1.1 Increasing prevalence of aortic valve stenosis to support market growth
7.1.2 OTHER THERAPY DEVICES

8 CATHETERS MARKET, BY TYPE
8.1 INTRODUCTION
8.1.1 ANGIOGRAPHY CATHETERS
8.1.1.1 Rising cases of artery disease and heart attacks to propel market
8.1.2 GUIDING CATHETERS
8.1.2.1 Increasing number of angiography procedures to drive the market
8.1.3 IVUS/OCT CATHETERS
8.1.3.1 Ability to obtain 3D images for aneurysm assessment to support market growth

9 ANGIOPLASTY BALLOONS MARKET, BY TYPE
9.1 INTRODUCTION
9.1.1 OLD/NORMAL BALLOONS
9.1.1.1 Low treatment costs associated with old/normal balloons to drive growth
9.1.2 DRUG-ELUTING BALLOONS
9.1.2.1 Rising number of regulatory approvals for drug-eluting balloons to support market growth during forecast period
9.1.3 CUTTING/SCORING BALLOONS
9.1.3.1 Limited use of cutting balloon-aided procedures to restrain market growth

10 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE
10.1 INTRODUCTION
10.1.1 THROMBECTOMY DEVICES
10.1.1.1 Ability to remove blood clots in STEMI and NSTEMI patients to propel market
10.1.2 ATHERECTOMY DEVICES
10.1.2.1 Increasing use of lipid-modifying drugs for atherosclerosis to support market growth

11 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE
11.1 INTRODUCTION
11.1.1 EMBOLIC PROTECTION DEVICES
11.1.1.1 Adoption of filter & occlusion-based devices to propel market
11.1.2 CHRONIC TOTAL OCCLUSION DEVICES
11.1.2.1 Uptake in treatment of total occlusions to drive market

12 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE
12.1 INTRODUCTION
12.1.1 GUIDEWIRES
12.1.1.1 Growing demand for stent placements and coronary intervention procedures to propel market
12.1.2 VASCULAR CLOSURE DEVICES
12.1.2.1 Ability to provide increased efficacy in patient outcomes to fuel uptake
12.1.3 INTRODUCER SHEATHS
12.1.3.1 Ability to provide secure access to blood vessels to support market growth
12.1.4 BALLOON INFLATION DEVICES
12.1.4.1 Increasing incidence of peripheral artery disease to drive market
12.1.5 HEMOSTASIS HEART VALVES
12.1.5.1 Growing focus on precision medicine

13 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER
13.1 INTRODUCTION
13.2 HOSPITALS
13.2.1 AVAILABILITY OF ADVANCED INFRASTRUCTURE AND SPECIALIZED EQUIPMENT TO DRIVE MARKET
13.3 AMBULATORY SURGERY CENTERS
13.3.1 LOW CASES OF HAIS AND SHORTER RECOVERY TIMES TO PROPEL MARKET
13.4 OTHER END USERS

14 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 US
14.2.2.1 Availability of reimbursements for cardiology procedures to drive market
14.2.3 CANADA
14.2.3.1 Rising prevalence of chronic diseases to drive market
14.3 EUROPE
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.3.2 GERMANY
14.3.2.1 Growing hub for advanced technology product distributors to drive market
14.3.3 FRANCE
14.3.3.1 Favorable government initiatives in France to support market growth
14.3.4 UK
14.3.4.1 Growing focus on personalized medicine to fuel uptake
14.3.5 ITALY
14.3.5.1 Increasing cases of obesity and CVD to support market growth
14.3.6 SPAIN
14.3.6.1 Increasing prevalence of age-related CVD conditions to drive market
14.3.7 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2 CHINA
14.4.2.1 High tobacco consumption and increasing cases of CVD to fuel uptake
14.4.3 JAPAN
14.4.3.1 Increasing demand for stents and catheters to support market growth
14.4.4 INDIA
14.4.4.1 Improvements in angioplasty devices to fuel uptake
14.4.5 AUSTRALIA
14.4.5.1 Increasing cases of lifestyle disorders to support market growth
14.4.6 SOUTH KOREA
14.4.6.1 Growth in pharmaceutical sectors to propel market
14.4.7 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 BRAZIL
14.5.2.1 Rising demand for quality treatment and focus on growing healthcare infrastructure to drive market
14.5.3 MEXICO
14.5.3.1 Increasing cases of diabetes to fuel market
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
14.6.2 GCC COUNTRIES
14.6.3 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET
15.3 REVENUE ANALYSIS
15.4 MARKET SHARE ANALYSIS
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.6 COMPANY FOOTPRINT
15.6.1 COMPANY FOOTPRINT: KEY PLAYERS, 2023
15.6.1.1 Company footprint
15.6.1.2 Region footprint
15.6.1.3 Product footprint
15.6.1.4 Angioplasty stents footprint
15.6.1.5 Structural heart devices footprint
15.6.1.6 Catheters footprint
15.6.1.7 Angioplasty balloons footprint
15.6.1.8 Plaque modification devices footprint
15.6.1.9 Hemodynamic flow alteration devices footprint
15.6.1.10 Other interventional cardiology devices footprint
15.6.1.11 End-user footprint
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
15.7.1 PROGRESSIVE COMPANIES
15.7.2 RESPONSIVE COMPANIES
15.7.3 DYNAMIC COMPANIES
15.7.4 STARTING BLOCKS
15.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
15.8 COMPANY VALUATION & FINANCIAL METRICS
15.8.1 FINANCIAL METRICS
15.8.2 COMPANY VALUATION
15.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
15.10 R&D ASSESSMENT OF KEY PLAYERS
15.11 COMPETITIVE SCENARIO
15.11.1 PRODUCT LAUNCHES & APPROVALS
15.11.2 DEALS
15.11.3 EXPANSIONS

16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 BOSTON SCIENTIFIC CORPORATION
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & approvals
16.1.1.3.2 Deals
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 MEDTRONIC
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches & approvals
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 ABBOTT
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches & approvals
16.1.3.3.2 Deals
16.1.3.4 MnM view
16.1.3.4.1 Key strengths
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 KONINKLIJKE PHILIPS N.V.
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Deals
16.1.5 TERUMO CORPORATION
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches
16.1.5.3.2 Expansions
16.1.5.4 MnM view
16.1.5.4.1 Key strengths
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses & competitive threats
16.1.6 EDWARDS LIFESCIENCES CORPORATION
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches & approvals
16.1.6.3.2 Deals
16.1.7 B. BRAUN SE
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches & approvals
16.1.7.3.2 Deals
16.1.8 INTEGER HOLDINGS CORPORATION
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.8.3.2 Expansions
16.1.9 TELEFLEX INCORPORATED
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product approvals
16.1.10 PENUMBRA, INC.
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches & approvals
16.1.11 COOK
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Deals
16.1.12 CORDIS
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches & approvals
16.1.12.3.2 Deals
16.1.13 IVASCULAR S.L.U.
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product launches
16.1.15 BIOTRONIK SE & CO. KG
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Product launches
16.2 OTHER PLAYERS
16.2.1 AMG INTERNATIONAL (SUBSIDIARY OF Q3 MEDICAL)
16.2.2 ENDOCOR GMBH & CO. KG
16.2.3 INSITU TECHNOLOGIES, INC.
16.2.4 MERIL LIFE SCIENCES PVT. LTD
16.2.5 ALVIMEDICA
16.2.6 CARDIONOVUM GMBH
16.2.7 MEDINOL
16.2.8 WELLINQ
16.2.9 BALTON SP.
16.2.10 TRANSLUMINA

17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS